alarpharm – 昱展新藥生技股份有限公司

2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019

Comments Off

11 . 8 . 2022

2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6

Comments Off

13 . 5 . 2022

2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.

Comments Off

13 . 5 . 2022

2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642

Comments Off

9 . 5 . 2022

2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q.

Comments Off

21 . 4 . 2022

2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence.

Comments Off

14 . 1 . 2022